Charles River Laboratories International Inc CRL Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$300.15 down $6.09, 1.99% at close Oct 16
Last close · Previous close $306.24
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$4.79Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$300.15down $6.09, 1.99%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$306.24Oct 15
- Volume674.59KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.02MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $146.20 to $333.30; now $300.15
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CRL beat the S&P 500 in 4 of 7 periods.
| Period | CRL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRL: up 9.8% S&P 500: up 1.5% | CRL beat the S&P 500 by 8.3 percentage points Beat |
| 3M | CRL: up 31.0% S&P 500: up 1.9% | CRL beat the S&P 500 by 29.1 percentage points Beat |
| YTD | CRL: up 50.5% S&P 500: up 12.8% | CRL beat the S&P 500 by 37.7 percentage points Beat |
| 1Y | CRL: up 71.6% S&P 500: up 16.8% | CRL beat the S&P 500 by 54.8 percentage points Beat |
| Long term | ||
| 3Y | CRL: up 55.7% S&P 500: up 81.5% +15.9% vs +22.0% a year | CRL trailed the S&P 500 by 25.8 percentage points Trailed |
| 5Y | CRL: down 25.6% S&P 500: up 83.1% −5.7% vs +12.9% a year | CRL trailed the S&P 500 by 108.7 percentage points Trailed |
| 10Y | CRL: up 272.6% S&P 500: up 319.6% +14.1% vs +15.4% a year | CRL trailed the S&P 500 by 47.0 percentage points Trailed |
$10,000 invested in CRL 10 years ago (Oct 14, 2016) would be worth about $37,263 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CRL beat the S&P 500 in 5 of 7 periods.
| Period | CRL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRL: up 9.8% S&P 500: up 1.2% | CRL beat the S&P 500 by 8.6 percentage points Beat |
| 3M | CRL: up 31.0% S&P 500: up 1.7% | CRL beat the S&P 500 by 29.3 percentage points Beat |
| YTD | CRL: up 50.5% S&P 500: up 11.9% | CRL beat the S&P 500 by 38.6 percentage points Beat |
| 1Y | CRL: up 71.6% S&P 500: up 15.5% | CRL beat the S&P 500 by 56.1 percentage points Beat |
| Long term | ||
| 3Y | CRL: up 55.7% S&P 500: up 75.0% +15.9% vs +20.5% a year | CRL trailed the S&P 500 by 19.3 percentage points Trailed |
| 5Y | CRL: down 25.6% S&P 500: up 71.2% −5.7% vs +11.4% a year | CRL trailed the S&P 500 by 96.8 percentage points Trailed |
| 10Y | CRL: up 272.6% S&P 500: up 258.1% +14.1% vs +13.6% a year | CRL beat the S&P 500 by 14.5 percentage points Beat |
$10,000 invested in CRL 10 years ago (Oct 14, 2016) would be worth about $37,263 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$458.30
Closing high on . Now 34.5% below that record.
Split-adjusted daily closes since Jun 23, 2000.
Stock splits
CRL hasn’t split since its price history begins in 2000.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 27, 2026. “Last 12 months” means the four quarters from Jun 29, 2025 to Jun 27, 2026, and balance-sheet figures are as of Jun 27, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $4.00Bdown 0.7%
- Net income
- −$238.46M
- Diluted EPS
- −$4.79
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 28, 2024) | $1.01B | $69.66M | $1.33 |
| Q4 FY24 (Dec 28, 2024) | $1.00B | −$214.50M | −$4.17 |
| Q1 FY25 (Mar 29, 2025) | $984.17M | $25.47M | $0.50 |
| Q2 FY25 (Jun 28, 2025) | $1.03B | $52.33M | $1.06 |
| Q3 FY25 (Sep 27, 2025) | $1.00B | $54.42M | $1.10 |
| Q4 FY25 (Dec 27, 2025) | $994.23M | −$276.56M | −$5.56 |
| Q1 FY26 (Mar 28, 2026) | $995.83M | −$14.84M | −$0.30 |
| Q2 FY26 (Jun 27, 2026) | $1.00B | −$1.48M | −$0.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 25, 2021) | $3.54B | $390.98M | $7.60 |
| FY22 (Dec 31, 2022) | $3.98B | $486.23M | $9.48 |
| FY23 (Dec 30, 2023) | $4.13B | $474.62M | $9.22 |
| FY24 (Dec 28, 2024) | $4.05B | $22.20M | $0.20 |
| FY25 (Dec 27, 2025) | $4.02B | −$144.34M | −$2.91 |
Margins
- Gross 32.7%
- Operating 2.3%
- Net −6.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $370.61MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$582.15MLast 12 months
- Capital spending$211.54MLast 12 months
- 9.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $321.74MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$321.74MLast 12 months
87% of free cash flow
Balance sheet
- $398.50MAs of Jun 27, 2026
Cash plus short- and long-term marketable securities on the Jun 27, 2026 balance sheet.
- Total debt$3.03BAs of Jun 27, 2026
- Net debt$2.63BAs of Jun 27, 2026
- 1.35As of Jun 27, 2026
Current assets divided by current liabilities on the Jun 27, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.07As of Jun 27, 2026
Total debt divided by shareholders’ equity on the Jun 27, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −7.7%Last 12 months
Over the last 12 months, Charles River Laboratories International lost money: its net loss was 7.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −3.2%Last 12 months
Over the last 12 months, Charles River Laboratories International’s net loss was 3.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Charles River Laboratories International Inc
Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
CRL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CRL stock FAQ
What is CRL stock’s price today?
Charles River Laboratories International (CRL) traded at $300.15 at the close on , down $6.09 (1.99%) from the previous close of $306.24. Over the past 52 weeks it has traded between $146.20 and $333.30.
If you invested $1,000 in CRL 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CRL on would be worth about $3,726 at the close on , a total return of +272.6%. The same $1,000 would be worth $744 if invested five years ago, $1,716 if invested one year ago, and $6,822 if invested 20 years ago. Past performance doesn’t predict future returns.
What is CRL’s P/E ratio?
CRL’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$4.79).
How much revenue does Charles River Laboratories International make?
Charles River Laboratories International reported $4.0 billion of revenue over the four quarters to , down 0.7% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $1.0 billion, down 2.7% from a year earlier.
Is Charles River Laboratories International profitable?
Not over the four quarters to . Charles River Laboratories International reported a net loss of $238.5 million across those four quarters on $4.0 billion of revenue. Its operations were still profitable before interest, other items and taxes, with $90.1 million of operating income.
What are CRL’s earnings per share?
CRL’s diluted earnings per share were −$4.79 over the four quarters to , compared with −$1.28 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.03 per share, against $1.06 a year earlier (how EPS works).
Does CRL pay a dividend?
Charles River Laboratories International hasn’t paid a dividend in the last twelve months.
What is CRL’s 52-week high and low?
Over the past 52 weeks CRL has traded as low as $146.20 and as high as $333.30. At $300.15 at the close on , it is 9.9% below that high and 105.3% above the low.
What is CRL’s all-time high?
CRL’s highest closing price was $458.30 on , adjusted for stock splits. At $300.15 at the close on , it is 34.5% below that record.
Has CRL stock ever split?
No. CRL hasn’t split since its price history begins in 2000.
How has CRL stock performed?
Including dividends and measured to the close on , CRL has returned +50.5% so far this year and +71.6% over the past year, and −25.6% over five years (−5.7% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Charles River Laboratories International in?
Charles River Laboratories International is in the Healthcare sector and the Diagnostics & Research industry, and is headquartered in Massachusetts, USA.
What exchange does CRL trade on?
Charles River Laboratories International trades on the NYSE under the ticker symbol CRL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.